Page last updated: 2024-12-04

2,4-dinitrophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1493
CHEMBL ID273386
CHEBI ID42017
SCHEMBL ID77643
SCHEMBL ID13973810
MeSH IDM0028729

Synonyms (144)

Synonym
MLS001066358
smr000471854
BIDD:ER0505
BRD-K21910317-001-02-4
nitrophen
nsc 1532
solfo black b
nitro kleenup
.alpha.-dinitrophenol
dinitrophenol
dinitrofenolo
nitrophene
solfo black g
phenol, .alpha.-dinitro-
solfo black bb
2,4-dinitrofenol
solfo black sb
tertrosulphur black pb
wln: wnr bq enw
tertrosulphur pbr
solfo black 2b supra
chemox pe
x 32
nsc-1532
fenoxyl carbon n
1-hydroxy-2,4-dinitrobenzene
2,4-dnp
nsc1532
aldifen
ek 102
DIVK1C_007034
alpha-dinitrophenol
maroxol-50
dinofan
tertrosulfur black pb
tertrosulfur pbr
sulphur black
sulphur black 1
dinitrofenolo [italian]
1'alpha-2,4-dinitrophenol
hsdb 529
osmotox-plus
caswell no. 392
nitrophene (van)
ccris 3102
rcra waste no. p048
2,4-dinitrofenol [dutch]
epa pesticide chemical code 037509
einecs 200-087-7
ai3-01535
nitrophen (van)
shirakiku brand mosquito coils
phenol, alpha-dinitro-
rcra waste number p048
osmoplastic-r
camello mosquito coils
AF-936/31262030
SPECTRUM_001934
SPECTRUM5_001670
BSPBIO_003248
phenol, 2,4-dinitro-
inchi=1/c6h4n2o5/c9-6-2-1-4(7(10)11)3-5(6)8(12)13/h1-3,9
dnf ,
NCGC00091778-01
2,4-dinitrophenol
C02496
51-28-5
2,4-dinitrophenol, moistened with water, >=98.0%
CHEBI:42017 ,
DB04528
NCGC00091778-02
NCGC00091778-03
KBIO2_005041
KBIO1_001978
KBIOSS_002480
KBIO2_002473
KBIO2_007609
KBIOGR_001406
KBIO3_002468
SPECTRUM3_001694
SPECTRUM4_000913
SPECTRUM2_000673
SPECPLUS_000938
SPBIO_000765
SPECTRUM330008
1326-82-5
NCGC00091778-04
STK397797
2,4-dinitrophenol, technical, moistened with water, >=97.0% (hplc)
D0109
chemox
mitcal
CHEMBL273386
sr-1c5
HMS1923K21
AKOS000118988
NCGC00091778-05
NCGC00091778-06
2,4-dinitro-phenol
q13sks21mn ,
unii-q13sks21mn
ec 200-087-7
tox21_300030
tox21_201462
NCGC00259013-01
NCGC00254114-01
dtxsid0020523 ,
dtxcid80523
cas-51-28-5
2,4-dinitrophenol (wetted with 15 % water)
HMS2233H07
CCG-39730
EPITOPE ID:112424
AKOS015912556
HMS3372P06
2,4-dinitrophenol [hsdb]
1,3-dinitro-4-hydroxybenzene
dinitrophenol [who-dd]
2,4-dinitrophenol [mi]
dinitrophenol [mart.]
SCHEMBL77643
SCHEMBL13973810
W-105909
AB00053210_08
mfcd00007115
2,4-dinitrophenol, saj special grade, >=98.0%
2,4-dinitrophenol, pestanal(r), analytical standard
phen-2,3,5-d3-ol,4,6-dinitro- (9ci)
2,4-dinitrophenol (h2o w/w 18% max)
AS-39888
Q209226
2,4-dinitrophenol, 96%, stab. with min. 15% water
BRD-K21910317-001-12-3
BRD-K21910317-001-06-5
HMS3867N13
2,4-dinitrophenol (wetted with up to 20per cent water)
nsc-791780
nsc791780
dinitrophenol, wetted
PD001942
EN300-19295
tatephosphate
2,4-dinitrophenol, wetted
Z104473446

Research Excerpts

Toxicity

2,4-Dinitrophenol (DNP) is reported to cause rapid loss of weight. DNP is associated with an unacceptably high rate of significant adverse effects.

ExcerptReferenceRelevance
"The toxicities of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats was examined and the susceptibility of newborn rats was analyzed in terms of presumed unequivocally toxic and no observed adverse effect levels (NOAELs)."( Comparative study of toxicity of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats.
Enami, T; Hasegawa, R; Ito, Y; Kamata, E; Koizumi, M; Takano, M; Yamamoto, Y, 2001
)
0.84
"The joint toxic effects of known binary and multiple organic chemical mixtures to the fathead minnow (Pimephales promelas) were defined at both the 96-h 50% lethal effect concentration (LC50) and sublethal (32-d growth) response levels for toxicants with a narcosis I, narcosis II, or uncoupler of oxidative phosphoralation mode of toxic action."( A comparison of the lethal and sublethal toxicity of organic chemical mixtures to the fathead minnow (Pimephales promelas).
Broderius, SJ; Elonen, GE; Hammermeister, DE; Hoglund, MD; Kahl, MD, 2005
)
0.33
" These data indicate that dinoseb is teratogenic at maternally toxic doses, but the exposure range of dinoseb at which malformations occur seems to be narrow."( Prenatal developmental toxicity of gavage or feeding doses of 2-sec-butyl-4,6-dinitrophenol in rats.
Ema, M; Fujii, S; Hirose, A; Matsumoto, M, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"2,4-Dinitrophenol (DNP) is reported to cause rapid loss of weight, but unfortunately is associated with an unacceptably high rate of significant adverse effects."( 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death.
Dargan, PI; El-Zanfaly, M; Grundlingh, J; Wood, DM, 2011
)
3.25
" The analogs 2a and 2b have submicromolar IC(50) values towards human HCT-116 colon cancer cells but are far less toxic to human non-malignant CRL-1790 colon cells."( Mitochondrial dysfunction contributes to the cytotoxicity of some 3,5-bis(benzylidene)-4-piperidone derivatives in colon HCT-116 cells.
Bandy, B; Das, U; Dimmock, JR; Helal, M; Islam, A; Nazarali, AJ, 2013
)
0.39
" 2,4-DNP and DNOC showed the highest tryptophan fluorescence quenching constant values, these being also the most toxic compounds."( Quenching of tryptophan fluorescence in the presence of 2,4-DNP, 2,6-DNP, 2,4-DNA and DNOC and their mechanism of toxicity.
Huţanu, CA; Pintilie, O; Zaharia, M, 2013
)
0.39
" We report a case of a 21-year-old bodybuilding enthusiast who presented with a toxic exanthem after taking 2,4-DNP, and describe the first skin biopsy findings in a case of 2,4-DNP toxicity."( Cutaneous drug toxicity from 2,4-dinitrophenol (DNP): Case report and histological description.
Kumarasinghe, SP; Le, P; Wood, B, 2015
)
0.71
" Of the compounds tested, 2,4-DNP was found to be highly toxic to the fish embryos following exposure."( Embryotoxicity of nitrophenols to the early life stages of zebrafish (Danio rerio).
Altıkat, AÖ; Ceylan, Z; Şişman, T; Yazıcı, Z, 2016
)
0.43
" Compared to inorganic arsenic, ROX was less toxic to wheat root elongation."( Phytotoxicity and uptake of roxarsone by wheat (Triticum aestivum L.) seedlings.
Blaney, L; Fu, QL; Zhou, DM, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability of nasal tetraethylammonium administration was 79%."( Nasal absorption of tetraethylammonium in rats.
Kato, Y; Kimura, R; Miwa, M; Sato, M; Yamada, S,
)
0.13
" At a low concentration, TMA was absorbed rapidly from the in situ intestinal lumen without being metabolized in the tissue and the rate of absorption was dependent upon the concentration used."( Intestinal absorption of tetramethylammonium and its derivatives in rats.
Komai, T; Tsubaki, H, 1986
)
0.27
" Dopamine deficiency has been associated with several neurological disorders; it has been shown to have good systemic bioavailability and significant uptake into the CNS following intranasal administration."( Metabolism of dopamine by the nasal mucosa.
Chemuturi, NV; Donovan, MD, 2006
)
0.33
" Reduced oxidative events with simultaneous increase in NO bioavailability may be involved in the insulin-sensitizing and cytoprotective effects of naringenin in fructose-fed rats."( Suppression of hepatic oxidative events and regulation of eNOS expression in the liver by naringenin in fructose-administered rats.
Anuradha, CV; Kannappan, S; Palanisamy, N, 2010
)
0.36
" In soil, successive replacement of -NO2 by -NH2 in DNAN enhanced irreversible sorption and reduced bioavailability under oxic conditions."( Environmental fate of 2,4-dinitroanisole (DNAN) and its reduced products.
Ampleman, G; Deschamps, S; Halasz, A; Hawari, J; Monteil-Rivera, F; Paquet, L; Perreault, NN; Radovic-Hrapovic, Z; Thiboutot, S, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
"[14C]Dinoseb was applied to previously clipped back skin of 33- and 82-day-old female Fischer 344 rats at a dosage range of 210-2680 nmol/cm2."( Age-related percutaneous penetration of 2-sec-butyl-4,6-dinitrophenol (dinoseb) in rats.
Fisher, HL; Hall, LL; Hughes, MF; Shah, PV; Sumler, MR, 1992
)
0.28
" When 1% bovine serum albumin was added to the isolation medium, DNP or FCCP stimulated ATPase nearly twofold and the dose-response curves for the uncouplers on the QO2 reached a plateau at five- to sixfold."( The insensitivity to uncouplers of testis mitochondrial ATPase.
Delhumeau-Ongay, G; Izquierdo-Reyes, V; Vázquez-Memije, ME, 1988
)
0.27
"Eleven groups of six ICR mice were dosed orally with 22."( Plasma levels and kinetic disposition of 2,4-dinitrophenol and its metabolites 2-amino-4-nitrophenol and 4-amino-2-nitrophenol in the mouse.
Hagardorn, AN; Robert, TA, 1985
)
0.54
" Uptake of [3H]DADLE was a receptor-mediated process, since it was inhibited by opiate receptor ligands and the (i) time course, (ii) dose-response curve, and (iii) temperature dependence of uptake were similar to those for enkephalin-receptor down regulation."( Characterization of the association of tritiated enkephalin with neuroblastoma cells under conditions optimal for receptor down regulation.
Blanchard, SG; Chang, KJ; Cuatrecasas, P, 1983
)
0.27
"Five groups of six ICR mice were orally dosed with 22."( Analysis and kinetics of 2,4-dinitrophenol in tissues by capillary gas chromatography--mass spectrometry.
Hagardorn, AN; Robert, TA, 1983
)
0.57
" Only cytochalasin A and 2-deoxy-D-glucose (2dG) affected bacterial internalisation, whereas intracellular multiplication was inhibited by cytochalasins A, B, C, D and J (D being the most active) and by 2dG with a dose-response effect."( Multiplication of Legionella pneumophila in HeLa cells in the presence of cytoskeleton and metabolic inhibitors.
Carrara, S; Cattani, L; Goldoni, P; Orsi, N; Pastoris, MC; Sinibaldi, L, 1998
)
0.3
" The infected mice that had been treated subsequently with adequate dosage of compound I or II had normal spleens, continued to live on, and had no integrated MMLV genome in their spleen and bone marrow samples."( Effective treatment of murine leukemia with antisense poly-2'O-(2,4-dinitrophenyl)-oligoribonucleotides.
Wang, A; Wang, JH, 1999
)
0.3
" As these statistical methods are not always satisfactory, some authors have proposed to describe the entire dose-response curves by fully formalized parametric regression models whose parameters have toxicological meaning."( Effects of dinoseb on the life cycle of Daphnia magna: modeling survival time and a proposal for an alternative to the no-observed-effect concentration.
Becker-van, SK; Behra, R; Brazzale, AR; Chèvre, N; Guettinger, H; Tarradellas, J, 2002
)
0.31
"4% in the high dosage groups."( Chemically induced supernumerary lumbar ribs in CD-1 mice: size distribution and dose response.
Branch, S; Chernoff, N; Rogers, JM; Setzer, RW, 2004
)
0.32
" Uses include screening compounds for gross metabolic effects in mammalian cell lines, determining preliminary metabolic dose-response curves for guiding further research, and designing and optimizing media for in vitro systems utilizing cell cultures."( 24-well plate spectrophotometric assay for preliminary screening of metabolic activity.
Balcarcel, RR; Yang, Y, 2003
)
0.32
"Models describing dose-response relationships are becoming increasingly popular in ecotoxicology."( Modeling the concentration-response function of the herbicide dinoseb on Daphnia magna (survival time, reproduction) and Pseudokirchneriella subcapitata (growth rate).
Becker-van Slooten, K; Behra, R; Brazzale, AR; Chèvre, N; Guettinger, H; Tarradellas, J, 2005
)
0.33
" The dose-response information for these metabolic regulators is crucial for designing future experiments."( Metabolic regulation of in-vitro-produced bovine embryos. I. Effects of metabolic regulators at different glucose concentrations with embryos produced by semen from different bulls.
De La Torre-Sanchez, JF; Preis, K; Seidel, GE, 2006
)
0.33
" Males were dosed for 46 days, beginning 14 days before mating, and females were dosed for 40-47 days, from 14 days before mating to day 3 of lactation."( Reproductive and developmental toxicity screening study of 2,4-dinitrophenol in rats.
Ema, M; Hirata-Koizumi, M; Hirose, A; Kamata, E; Sunaga, M; Takahashi, M, 2009
)
0.6
" A dosage of antibiotics initially increased the heat production rate."( Chip calorimetry for fast and reliable evaluation of bactericidal and bacteriostatic treatments of biofilms.
Buchholz, F; Harms, H; Lerchner, J; Maskow, T; Mertens, F; Wolf, A, 2010
)
0.36
" Additionally, we discuss the use of dantrolene in dinitrophenol poisoning and question whether current Toxbase/UK National Poison Information Service treatment guidelines regarding the indication and dosing of this drug, the only relatively specific treatment in dinitrophenol poisoning presently recommended, could be revised."( 'Fatal 2,4-dinitrophenol poisoning... coming to a hospital near you'.
Narasimhaiah, R; Siegmueller, C, 2010
)
0.82
" The feasibility analysis was focused on the adsorption effects of various factors, such as initial concentration, adsorbent dosage and reaction time."( Potential application of chicken manure biochar towards toxic phenol and 2,4-dinitrophenol in wastewaters.
Giang, BL; Huong, PT; Jitae, K; Thang, PQ; Viet, NM, 2019
)
0.75
"The findings highlighted diverse motivations for why women use DNP as well as differences in experiences, dosing regimens, willingness to take risks and adverse effects."( 2,4 dinitrophenol: It's not just for men.
Germain, DJ; Leavey, DC; McVeigh, PJ; Van Hout, PMC, 2021
)
0.62
" Users equate deaths or ill harms from DNP with incorrect dosing or insufficient knowledge of the impact of the drug on the body."( 2,4 dinitrophenol: It's not just for men.
Germain, DJ; Leavey, DC; McVeigh, PJ; Van Hout, PMC, 2021
)
0.62
"Micro-aeration hydrolysis acidification (HA) is an effective method to enhance the removal of toxic and refractory organic matter, but the difficulty in stable dosing control of trace oxygen limits its wide application."( Coupling of membrane-based bubbleless micro-aeration for 2,4-dinitrophenol degradation in a hydrolysis acidification reactor.
Guo, Z; Wu, C; Xi, H; Yang, Y; Yu, Y; Zhang, Z; Zhou, Y, 2022
)
0.97
" Additional immune-histochemical analysis of inflammation markers and remyelination of the sciatic nerves were performed for the dosage of 1 mg/kg and control."( 2,4-Dinitrophenol does not exert neuro-regenerative potential in experimental autoimmune neuritis.
Ackfeld, R; Barham, M; Fink, GR; Grandoch, A; Klein, I; Kohle, F; Lehmann, HC; Schneider, C; Svačina, MKR; van Beers, T, 2023
)
2.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
oxidative phosphorylation inhibitorAny compound that inhibits oxidative phosphorylation.
bacterial xenobiotic metaboliteAny bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria.
antiseptic drugA substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body).
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dinitrophenolMembers of the class of nitrophenol carrying two nitro substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (43)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
acetylcholinesteraseHomo sapiens (human)Potency73.04770.002541.796015,848.9004AID1347395; AID1347397; AID1347399
pregnane X receptorRattus norvegicus (Norway rat)Potency50.11870.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency20.07750.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency30.34460.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency36.57430.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.37090.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency15.41780.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency39.75890.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency38.62900.000214.376460.0339AID588533; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency77.27200.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.53570.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.07030.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency39.48310.000229.305416,493.5996AID1259244; AID1259248; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency19.95260.00018.4406100.0000AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency9.81190.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.96620.001019.414170.9645AID743140
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency55.05870.023723.228263.5986AID743222; AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency45.10200.000723.06741,258.9301AID743085; AID743122
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency19.95260.316212.443531.6228AID924
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency25.11890.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00560.010039.53711,122.0200AID588545
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency35.48133.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency63.32330.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency31.10270.037617.082361.1927AID1259364; AID1259388
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency41.89380.000627.21521,122.0200AID651741; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency24.08750.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.28180.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency11.22020.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency11.22020.251215.843239.8107AID504327
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency48.65650.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency43.45320.002319.595674.0614AID651631
Integrin beta-3Homo sapiens (human)Potency19.95260.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency19.95260.316211.415731.6228AID924
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency48.65650.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency6.68240.026622.448266.8242AID651802
TAR DNA-binding protein 43Homo sapiens (human)Potency15.84891.778316.208135.4813AID652104
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency5.69870.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency5.37200.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (234)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (65)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (57)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (79)

Assay IDTitleYearJournalArticle
AID1512634Toxicity in po dosed rat2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential.
AID1063469Antibacterial activity against Escherichia coli ATCC 700927 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID1063470Antibacterial activity against Streptococcus mutans ATCC 700610 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID1063473Antibacterial activity against Lactobacillus casei ATCC 334 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID580626Disruption of bacterial membrane permeability in Bacillus subtilis BD54 using DiSC3 fluorescent dye staining based fluorimetric assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID127482Ability to bind to monoclonal antibody IgE (Lb4), expressed as association constant (LogKA)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Comparative molecular field analysis of haptens docked to the multispecific antibody IgE(Lb4)
AID195261Uncoupler concentration that reduced the respiratory control index by 50% of coupled rat liver mitochondria1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and endectocidal activity of novel 1-(arylsulfonyl)-1-[(trifluoromethyl)sulfonyl]methane derivatives.
AID1063468Antibacterial activity against Enterococcus faecalis ATCC 47077 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID329523Toxicity in rat striatal neuronal N548 mutant cells2007Proceedings of the National Academy of Sciences of the United States of America, Sep-04, Volume: 104, Issue:36
Inhibitors of metabolism rescue cell death in Huntington's disease models.
AID329524Cell death rescue in rat striatal neuron N548 mutant cells relative to rotenone2007Proceedings of the National Academy of Sciences of the United States of America, Sep-04, Volume: 104, Issue:36
Inhibitors of metabolism rescue cell death in Huntington's disease models.
AID1512633Toxicity in human assessed as weight loss2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1063472Antibacterial activity against Lactobacillus reuteri ATCC 23272 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID584825Inactivation of Pseudomonas putida PAW340 biofilms assessed as decrease in heat production at 0.5 mM by Chip calorimetry2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Chip calorimetry for fast and reliable evaluation of bactericidal and bacteriostatic treatments of biofilms.
AID25078The pKa value in aqueous solution.1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and endectocidal activity of novel 1-(arylsulfonyl)-1-[(trifluoromethyl)sulfonyl]methane derivatives.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID756648Effect on ATL level in rat L6 cells at 3.5 mmol/L after 20 mins in presence of HCGM (Rvb = 23 mmol/L)2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.
AID1063476Antibacterial activity against Bacteroides fragilis ATCC 25285 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID584833Inactivation of Pseudomonas putida PAW340 biofilms assessed as decrease in heat production at 0.5 mM within 1 hr by Chip calorimetry2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Chip calorimetry for fast and reliable evaluation of bactericidal and bacteriostatic treatments of biofilms.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID329496Cell death rescue in rat striatal neuron N548 mutant cells2007Proceedings of the National Academy of Sciences of the United States of America, Sep-04, Volume: 104, Issue:36
Inhibitors of metabolism rescue cell death in Huntington's disease models.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1488503Stimulation of mitochondrial respiration in Wistar rat liver microsomes assessed as oxygen consumption rate at 20 and 25 uM using pyruvate and malate as respiratory substrate after 4 mins2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
3,5-Bis(3-dimethylaminomethyl-4-hydroxybenzylidene)-4-piperidone and related compounds induce glutathione oxidation and mitochondria-mediated cell death in HCT-116 colon cancer cells.
AID1299637Bactericidal activity against Pseudomonas aeruginosa PAO1 ATCC 47085 assessed as reduction in bacterial burden2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Antibacterial Diamines Targeting Bacterial Membranes.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID584826Inactivation of Pseudomonas putida PAW340 biofilms assessed as decrease in ATP content at 0.5 mM by Chip calorimetry2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Chip calorimetry for fast and reliable evaluation of bactericidal and bacteriostatic treatments of biofilms.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID303044Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID389779Activation of AMPKalpha in rat L6 cells assessed as ATP concentration per mg of protein at 5 mM after 10 mins in presence of 23 mM D-glucose2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1299636Bactericidal activity against Staphylococcus aureus RN4220 ATCC 35556 assessed as reduction in bacterial burden2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Antibacterial Diamines Targeting Bacterial Membranes.
AID329498Toxicity in drosophila Huntington's disease model2007Proceedings of the National Academy of Sciences of the United States of America, Sep-04, Volume: 104, Issue:36
Inhibitors of metabolism rescue cell death in Huntington's disease models.
AID267573Antiproliferative activity against human HL60 cell line2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.
AID1063477Antibacterial activity against Clostridium perfringens ATCC 13124 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1054848Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis after 30 mins by turbidimetric assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID329522Cell death rescue of neuronal cells in drosophila Huntington's disease model2007Proceedings of the National Academy of Sciences of the United States of America, Sep-04, Volume: 104, Issue:36
Inhibitors of metabolism rescue cell death in Huntington's disease models.
AID1054847Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis at 40 uM after 30 mins by turbidimetric assay relative to control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1512635Toxicity in dog2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1063478Antibacterial activity against Clostridium difficile CD196 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID726457Reduction in mitochondria membrane potential in human HCT116 cells measured as fluorescence units at 1 uM after 48 hrs by JC-1 dye (negative control = 3069 +/- 20 Flu_intensity)2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Mitochondrial dysfunction contributes to the cytotoxicity of some 3,5-bis(benzylidene)-4-piperidone derivatives in colon HCT-116 cells.
AID19687Partition coefficient (logP) (HPLC)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and endectocidal activity of novel 1-(arylsulfonyl)-1-[(trifluoromethyl)sulfonyl]methane derivatives.
AID1063475Antibacterial activity against Bacteroides thetaiotaomicron ATCC 29148 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID329497Toxicity in Caenorhabditis elegans Huntington's disease model2007Proceedings of the National Academy of Sciences of the United States of America, Sep-04, Volume: 104, Issue:36
Inhibitors of metabolism rescue cell death in Huntington's disease models.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1063474Antibacterial activity against Bifidobacterium longum ATCC BAA-999 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID390924Inhibition of Escherichia coli HisG2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID303043Cytotoxicity against human MIA PaCa2 cells after 4 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID329499Cell death rescue of ASH neuronal cells in Caenorhabditis elegans Huntington's disease model2007Proceedings of the National Academy of Sciences of the United States of America, Sep-04, Volume: 104, Issue:36
Inhibitors of metabolism rescue cell death in Huntington's disease models.
AID1512641Dissociation constant, pKa of compound2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Small Molecule Mitochondrial Uncouplers and Their Therapeutic Potential.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1063471Antibacterial activity against Staphylococcus aureus 8325-4 assessed as growth inhibition after 20 to 24 hrs2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,723)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990737 (42.77)18.7374
1990's378 (21.94)18.2507
2000's314 (18.22)29.6817
2010's243 (14.10)24.3611
2020's51 (2.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.11%)5.53%
Reviews18 (0.98%)6.00%
Case Studies27 (1.48%)4.05%
Observational0 (0.00%)0.25%
Other1,782 (97.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]